If you have been reading about LY3437943 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-11. Numbers and descriptions here follow the published literature rather than marketing material.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| 长期储存温度 | 约 -20°C 或更低 | 冻干粉常见保存条件 |
| 复溶溶剂 | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器材质 | 低吸附聚丙烯 | 减少多肽在管壁的吸附损失 |
| 主要降解路径 | 脱酰胺、氧化、聚集 | 由序列与工艺条件共同决定 |
| 追溯材料 | 分析证书与批次记录 | 用于来源与纯度核实 |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
COVID-19 apps include mobile-software applications for digital contact-tracing—i.e. the process of identifying persons ("contacts") who may have been in contact with an infected individual—deployed during the COVID-19 pandemic. Numerous tracing applications have been developed or proposed, with official government support in some territories and jurisdictions. Several frameworks for building contact-tracing apps have been developed. Privacy concerns have been raised, especially about systems that are based on tracking the geographical location of app users. Less overtly intrusive alternatives include the co-option of Bluetooth signals to log a user's proximity to other cellphones. (Bluetooth technology has form in tracking cell-phones' locations.)) On 10 April 2020, Google and Apple jointly announced that they would integrate functionality to support such Bluetooth-based apps directly into their Android and iOS operating systems. India's COVID-19 tracking app Aarogya Setu became the world's fastest growing application—beating Pokémon Go—with 50 million users in the first 13 days of its release. (Full article...)
There is much criticism indicating that the Nova classification refers to formulation and additives while processing levels must relate to unit operations and food processing. Food processing categories with typical processes are given in Table 1.
Methods used for desulfurization include, among others, hydrodesulfurization, oxidative desulfurization, extractive desulfurization, and extraction by ionic liquids. Despite their efficiency at reducing sulfur content, the conventional desulfurization methods are still accountable for a significant amount of the CO2 emissions associated with the crude oil refining process, releasing up to 9000 metric tons per year. Furthermore, these processes usually require large amounts of energy, and are accompanied by massive costs for the industries that employ them. A greener and also complementary alternative process to the conventional desulfurization methods is biodesulfurization.
Lord Norton, a former Oxford classmate of Charles’, tells Yasmin he always knew Charles to be a sexual predator going back to his Oxford days. Later, Yasmin hires Alondra—the woman from the yacht—who implies Charles abused girls as young as twelve and gently suggests Yasmin may have been a victim as well, causing Yasmin to break down. At the end of series 4, Yasmin, who has herself become a predatory figure by trafficking escorts to powerful men, repeatedly listens to Charles' final voicemail inviting her on the boat trip.
Sources: en.wikipedia.org
The Central Command adds it struck roughly 140 military targets in Iran after the attack. CENTCOM declares that the strait is "open to all vessels" and "Iran does not control" it. CENTCOM announces that it conducted additional strikes on dozens of Iranian targets over attacks against vessels to further degrade the regime's capability to attack civilian sailors and commercial ships in the strait. The US forces use suicide drone boats in combat for the first time to strike an Iranian submarine and ship maintenance facility at Bandar Abbas Naval Base. Mitch McConnell releases a statement amidst ongoing speculation about his health, stating he was hospitalized for pneumonia. July 13 2026 Iran war: Trump announces that the US will reinstate the "Iranian blockade in the Strait of Hormuz" and impose a 20% toll on cargo shipping through the strait. According to Trump, "The U.S.A. will be, from this point forward, known as 'THE GUARDIAN OF THE HORMUZ STRAIT.'" Trump describes it as a matter of fairness, claiming that the toll would cover "any and all costs necessary to do the job of providing safety and security to this very volatile section of the world." American-led Combined Maritime Forces' Joint Maritime Information Centre (JMIC) announces that the US naval blockade on Iran will start the following day. Trump formally informs the US Congress that the country has renewed hostilities against Iran. Trump declares that the US will hit Iran hard on that day and the next day, saying that the MoU was a test that the regime did not honor.
{\displaystyle {\begin{array}{rcl}\\{\ce {^{3}_{1}H}}&{\ce {->[12.32\ {\ce {y}}]}}&{\ce {{^{3}_{2}He}+e^{-}}}\\{\ce {^{4}_{1}H}}&{\ce {->[139\ {\ce {ys}}]}}&{\ce {{^{3}_{1}H}+{^{1}_{0}n}}}\\{\ce {^{5}_{1}H}}&{\ce {->[86\ {\ce {ys}}]}}&{\ce {{^{3}_{1}H}+{2_{0}^{1}n}}}\\{}\end{array}}}
Dapagliflozin was authorized for medical use in the European Union in November 2012. It is sold in a number of European countries. Dapagliflozin was approved for medical use in the United States in January 2014. In 2020, the US FDA expanded the indications for dapagliflozin to include treatment for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure. It is the first in this particular drug class, sodium-glucose co-transporter 2 inhibitors, to be approved to treat adults with New York Heart Association's functional class II-IV heart failure with reduced ejection fraction. In the DAPA‑HF clinical trial, when dapagliflozin was added to standard therapy in adults with symptomatic heart failure and reduced ejection fraction, the risk of worsening heart failure or cardiovascular death was reduced. It also reduced the risk of death from any cause (approximately 17% lower risk) compared with placebo over an average of about 18 months. In DECLARE‑TIMI 58, a clinical trial which included adults with type 2 diabetes and cardiovascular risk, dapagliflozin reduced heart failure hospitalisations and improved the combined outcome of death from a heart related cause or heart failure hospitalisation. However, dapagliflozin did not reduce the overall number of deaths from any cause compared with placebo when all participants were considered together. The safety and effectiveness of dapagliflozin were evaluated in a randomized, double-blind, placebo-controlled study of 4,744 participants.
The structure of the People's Armed Police is complex, and has highly varied over time. While the majority of PAP units are involved in standard policing and gendarmerie duties, the PAP has also included at different times unique specialised units. The People's Armed Police was established in 1982, taking over duties from previous units and formations that directly under the command of the People's Liberation Army. The PAP reports directly to the Central Military Commission (CMC) of the Chinese Communist Party (CCP).
==== Regrowing teeth ==== In 2004, scientists at King's College London discovered a way to cultivate a complete tooth in mice and were able to grow bioengineered teeth stand-alone in the laboratory. Researchers are confident that tooth regeneration technology can be used to grow live teeth in people. In theory, stem cells taken from the patient could be coaxed in the lab turning into a tooth bud which, when implanted in the gums, will give rise to a new tooth, and would be expected to be grown in a time over three weeks. It will fuse with the jawbone and release chemicals that encourage nerves and blood vessels to connect with it. The process is similar to what happens when humans grow their original adult teeth. Many challenges remain, however, before stem cells can be a choice for the replacement of missing teeth in the future.
Sources: en.wikipedia.org
== Distribution and habitat == The croaking gourami is native to stillwater habitats including ponds, canals and paddy fields in Java, Borneo, Sumatra, Malaya, Thailand, Laos, Cambodia, and Vietnam. A breeding population is known to exist in a series of drainage ditches in Florida; this population is almost certainly introduced there through the aquarium trade.
Osedax is a genus of siboglinid polychaetes, commonly called snot worms, bone-eating worms, or zombie worms. Osedax is Latin for 'bone devourer', derived from the worms' unique ecological niche of bone-boring. Osedax settle on a bone, then secrete an acid through specialized root tissues to dissolve the bone's external layers in order to access the lipids within. Osedax act as ecosystem engineers, enhancing the biodiversity of bones they inhabit by increasing their structural complexity, allowing microfauna to inhabit otherwise inaccessible regions of the internal bone. Scientists from the Monterey Bay Aquarium Research Institute using the submarine ROV Tiburon first discovered the genus in Monterey Bay, California, in February 2002. The worms were found living on the bones of a decaying gray whale in the Monterey Canyon, at a depth of 2,893 m (9,491 ft).
=== Intramuscular or intravenous injection === Injection of hydroxycobalamin is often used if digestive absorption is impaired, but this course of action may not be necessary with high-dose oral supplements (such as 0.5–1.0 mg or more), because with large quantities of the vitamin taken orally, even the 1% to 5% of free crystalline B12 that is absorbed along the entire intestine by passive diffusion may be sufficient to provide a necessary amount. A person with cobalamin C disease, a rare autosomal, recessive, inheritance disease which results in combined methylmalonic aciduria and homocystinuria), can be treated with intravenous or intramuscular hydroxocobalamin.
=== Inulin === The GFR can be determined by injecting inulin or the inulin analog sinistrin into the blood stream. Since both inulin and sinistrin are neither reabsorbed nor secreted by the kidney after glomerular filtration, their rate of excretion is directly proportional to the rate of filtration of water and solutes across the glomerular filter. Incomplete urine collection is an important source of error in inulin clearance measurement. Using inulin to measure kidney function is the "gold standard" for comparison with other means of estimating glomerular filtration rate. In 2018, the French pharmacovigilance agency withdrew inulin and sinistrin-based products from the market after some patients experienced hypersensitivity reactions including a fatal outcome. Consequently, the contrast agents iohexol and iothalamate have become more popular alternatives to determine GFR and are considered to show sufficient accuracy to determine GFR.
Sources: en.wikipedia.org
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。
低温可以降低水解与聚集的速率，从而延缓降解进程。温度反复波动本身也可能造成相变与样品损失。稳定的储存条件是可重复结果的前提。
分析证书、批次编号、所用检测方法与结果，以及标称储存条件。缺少方法细节的报告难以独立复核。记录完整性决定了追溯能否成立。
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.